IMCR · Immunocore Holdings plc
AI read · Neutral
The AI's read
This is an analyst's unchanged view of the shares, not news about Immunocore's sales, medicines, or plans. It gives no new reason to change how we read the company.
Morgan Stanley says to keep your shares in Immunocore Holdings plc for now.
Neutral
Morgan Stanley kept its rating and $43 share-price target for Immunocore unchanged. This is an analyst's view, not new company news, so it does not change the company's outlook.
Get alerts for IMCR
Follow Immunocore Holdings plc (IMCR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IMCRFree on the App Store and Google Play, or on the web.